Objective:The SWOG S1609 Dual Anti-CTLA-4 progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR; overall response plus stable disease SD 6 months), and toxicity are secondary endpoints.Results: Seven evaluable patients (median age, 60 years; performance status 0-1; no prior exposure to immunotherapy) were analyzed, of whom 3 had adenocarcinoma, 2 had squamous cell carcinoma (SCC), one had small-cell carcinoma and one had undifferentiated histology.The ORR was 29%, with 1 patient (14%) with undifferentiated histology achieving complete response (lasting 14.8 months) and 1 patient with SCC histology (14%) attaining a partial response (lasting 45.2 months).The CBR was 43%.The 6-month PFS rate
Chae et al. (Thu,) studied this question.